ARQ 197: Novel c-MET inhibitor shows promise in early clinical trial results with Tarceva


Earlier this week, the Boston (Woburn, actually)-based company Arqule announced preliminary results from a trial of their investigational oral c-MET inhibitor ARQ 197 combined with the EGFR inhibitor Tarceva (erlotinib), which sent their stock soaring. Although I and other investigators dislike learning about potentially important cancer trial outcomes from the business news outlets, this was again following that pattern.

Subscribe to ARQ 197